Previous 10 | Next 10 |
Shares of Co-Diagnostics Inc. (NASDAQ:CODX) traded at a new 52-week high today of $31.57. This new high was reached on above average trading volume as 249.4 million shares traded hands, while the average 30-day volume is approximately 466,000 shares. Co-Diagnostics Inc. (NASDAQ:CODX) has...
Co-Diagnostics' Q3 2021 earnings call touted its inexpensive, fast, accurate Eikon testing platform with gold standard PCR results. The Q4 earnings call made no mention of Eikon; now it is touting its "Co-Dx YourTest PCR device", a simple name change perhaps, but there is a hitch. ...
Investors were none too happy with Co-Diagnostics (NASDAQ: CODX) on Friday. They traded the stock down by almost 12% following the release of full-year 2021 results. For the year, Co-Diagnostics posted revenue of just under $98 million, which was a 31% improvement over the 2020 ...
Co-Diagnostics, Inc. (CODX) Q4 2021 Results Conference Call March 24, 2022 04:30 PM ET Company Participants Andrew Benson - Head, IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Yi Chen - H.C. Wainwright Jim Sidoti - Sidoti & Company Theodore O’Neill - Litchfiel...
COVID-19 test maker, Co-Diagnostics (NASDAQ:CODX) has made modest gains in the post-market Thursday after reporting a decline in the net income despite a topline growth for 2021. Revenue for the year jumped ~31% YoY to $97.9M, mainly driven by worldwide sales of Logix Smart COVID-19 Test...
Co-Diagnostics press release (NASDAQ:CODX): FY GAAP EPS of $1.23 beats by $0.13. Revenue of $97.89M (+31.3% Y/Y) misses by $0.53M. Gross profit increased to $86.3 million year-over-year, representing 88.2% of consolidated revenue. Operating income improved to $46.1 million due to record reven...
Co-Diagnostics Reports Full Year 2021 Financial Results PR Newswire Achieved Record Full Year Revenue of $97.9 Million ; Strength in Sales Momentum Provides Foundation to Achieve Solid FY'22 SALT LAKE CITY , March 24, 2022 /PRNewswire/ -- ...
Co-Diagnostics (NASDAQ:CODX) is scheduled to announce FY earnings results on Thursday, March 24th, after market close. The consensus EPS Estimate is $0.12 (-92.1% Y/Y) and the consensus Revenue Estimate is $98.42M (+32.0% Y/Y). For further details see: Co-Diagnostics FY 2021 Earnings Pr...
ADMA, BEAT, CLVR, CODX, CURI, HNST, OTCQB:IGXT, JOBY, LFC, MAXN, NIO, ONL, OSS, SGLB, TMC For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Thursday's close
Co-Diagnostics, Inc. to Present at MarketsandMarkets Conference on March 23-24 in London, England PR Newswire SALT LAKE CITY , March 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a u...
News, Short Squeeze, Breakout and More Instantly...
Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago PR Newswire SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company wi...
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the developme...
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States PR Newswire SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company w...